News
- Author:
- Kate Johnson
Publish date: April 15, 2020
The oncologist treating a patient should not make decisions about resource allocation for that patient, ASCO says.
News
- Author:
- Kate Johnson
Publish date: April 13, 2020
Their story, one of two people living together but with such different responses to the infection, illustrates how much is still to be learned abou...
News
- Author:
- Kate Johnson
Publish date: April 6, 2020
New guidelines recommend giving palliative radiotherapy only in oncologic emergencies during the COVID-19 pandemic.
News
- Author:
- Kate Johnson
Publish date: April 1, 2020
Oncologists are moving cancer patients to other hospitals, reevaluating the need for cancer treatments, and embracing telemedicine to protect vulne...
News
- Author:
- Kate Johnson
Publish date: February 25, 2020
It’s past time to call the novel coronavirus, COVID-19, a pandemic and “time to push people to prepare, and guide their prep,” risk communication e...
News
- Author:
- Kate Johnson
Publish date: February 14, 2011
Major Finding: An increase in cognitive, behavioral, and physical problems was seen among offspring of women who were pregnant during or immediate...
News
- Author:
- Kate Johnson
Publish date: February 1, 2011
News
- Author:
- Kate Johnson
Publish date: February 1, 2011
News
- Author:
- Kate Johnson
Publish date: February 1, 2011
News
- Author:
- Kate Johnson
Publish date: January 1, 2011
News
- Author:
- Kate Johnson
Publish date: January 1, 2011
News
- Author:
- Kate Johnson
Publish date: December 15, 2010
Major Finding: Global HRQOL scores at 9 months were significantly worse in patients who received WBRT than in those who underwent observation alon...
News
- Author:
- Kate Johnson
Publish date: December 9, 2010
Major Finding: More than half of patients with a median Karnofsky performance score of 60 improved their score by at least 10 points.Data Source: ...
News
- Author:
- Kate Johnson
Publish date: December 3, 2010
Major Finding: Two phase II studies of vatalanib and sunitinib showed 6-month progression-free survival rates of 57% and 36%, respectively.Data So...
News
- Author:
- Kate Johnson
Publish date: December 3, 2010
Major Finding: Two phase II studies of vatalanib and sunitinib showed 6-month progression-free survival rates of 57% and 36%, respectively.Data So...
